Skip to content

Efficacy of Neurofeedback treatment on Anxiety

Efficacy of QEEG Guided Neurofeedback treatment on decreasing symptoms and signs of Generalized Anxiety Disorder and emotion regulation strategies.

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20171102037181N1
Enrollment
30
Registered
2018-01-21
Start date
2018-01-31
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Generalized Anxiety Disorder. Generalized anxiety disorder

Interventions

Intervention group: 15 subjects will be treated on the basis of QEEG-based neurofeedback training, and 15 subjects will not receive any intervention in the control group, and individual treatment will
Treatment - Devices

Sponsors

Zanjan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Having DSM-5 diagnostic criteria for generalized anxiety disorder diagnosed by a psychiatrist based on diagnostic interview and clinical psychologist; as well as on the basis of the 7-item GAD-7 questionnaire and DSM-5 Clinical Interview for generalized Anxiety Disorder At least 18 years and maximum 50 years Study at one of the academic levels Patient agrees to participate in research and sign a written consent

Exclusion criteria

Exclusion criteria: Suffering Psychotic disorder And Substance Abuse Based on Diagnostic Interview. Not receiving psychological treatment at least 6 months before entering the research. No drug use at least one month before entering the research. Having complete criteria for personality disorder in axis II based on diagnostic interview. The apparent risk of suicide is now. Having more than two absentee sessions.

Design outcomes

Primary

MeasureTime frame
The severity of the signs and symptoms of generalized anxiety disorder. Timepoint: The effect of neurofeedback treatment in patients with generalized anxiety disorder before, after and three months after treatment. Method of measurement: The score that the subject gained from the GAD-7 questionnaire is the GAD-7. This scale has been developed to diagnose anxiety disorder and to measure the severity of clinical symptoms.

Secondary

MeasureTime frame
Emotional regulation. Timepoint: Evaluating the improvement of emotional regulation strategies before, after and three month following the treatment of neurofeedback. Method of measurement: The score for the subject of the Emotional Regulation Strategies Questionnaire (ERQ; Grass & John, 2003) was designed to evaluate two emotion regulation strategies, including suppression and re-evaluation. This questionnaire has 10 sentences.;Anxiety. Timepoint: Evaluation before, after, and in the following three months. Method of measurement: The score that the subject obtained from the Depression, Anxiety and Stress Questionnaire (DASS).;Depending on the DSM-5 criteria, depression involves a number of disorders that all agree on three types of symptoms: mood symptoms that include: feeling sad, empty, worrying and irritable. Vegetative symptoms that include fatigue, social deprivation and diabetes. Disturbances in appetite (depression or increased sleep) are also common. The cognitive symptoms of these disorders include centralized problems, difficulty in resolving, low self confidence, negative thoughts about oneself, the world, and others, and guilty and suicidal ideation. Timepoint: Evaluation before, after, and in the following three months. Method of measurement: The score that the subject obtained from the Depression, Anxiety and Stress Questionnaire (DASS).

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHasan Abdiyan Kalibar

Zanjan University of Medical Sciences

h.abdiyan25@yahoo.com+98 24 3354 2401

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026